Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial

The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.